Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BP-002
- Development stage
- Unknown
- Lead developer
- BioMap
- Modality
- Drug Delivery Systems
- Administration
- Oral
01
Overview
**BP-002** is a Brillian Pharma pediatric oral unit-dose reformulation program categorized by the company as an **antibiotic plus an inhibitor**. It is described as an oral suspension or lyophilized unidose product intended to adapt an existing antibiotic-inhibitor combination for pediatric use. The publicly available pipeline information does not disclose the constituent active ingredients, molecular targets, specific indication, or development phase. ([brillianpharma.com](https://brillianpharma.com/our-products/pipeline/))
- Other names
- BP 002BP002BP-002
Beyond the preview
Go deeper on BP-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BP-002.